Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FluMist Pharmacy Administration In 36 States Upon Approval – MedImmune

Executive Summary

MedImmune expects pharmacists in 36 states to administer FluMist to patients upon launch of the intranasal flu vaccine, President Melvin Booth said
Advertisement

Related Content

MedImmune Aims To Double Pharmacies Offering FluMist; WalMart Passes
MedImmune Aims To Double Pharmacies Offering FluMist; WalMart Passes
FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser
FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser
MedImmune FluMist Capacity Could Reach 20 Mil. Doses For 2004 Season
Wyeth FluMist Draft Label Will Be Reviewed By CDC Cmte. To Speed Coverage
FluMist Comparison To Inactivated Vaccine Suggested By FDA Committee
FluMist Comparison To Inactivated Vaccine Suggested By FDA Committee
FluMist Initial Indication May Exclude Patients Under Age Five
Wyeth/Aviron FluMist Pulmonary Safety Requires More Analysis - FDA Cmte.
Advertisement
UsernamePublicRestriction

Register

PS041526

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel